GSK plc (GSK)

GSK plc's Q·Score is 6.3/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 41% return on equity and 18% profit margins. Key area to monitor: cautious analyst consensus — few Buy ratings. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for GSK is $57.65, based on ratings from 8 Wall Street analysts. This is 11.7% above the current price of $51.61. Price targets are forward-looking estimates and not guarantees of future performance.

GSK plc (GSK) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 9.9×. The consensus analyst price target of $57.65 is 12% above the current price.

GSK plc's next earnings report is expected on approximately July 29, 2026.

GSK plc has a net profit margin of 17.8%, which is solid for most industries. Its gross margin stands at 72.9%, indicating a high-margin business model.

GSK plc currently offers a dividend yield of 3.49%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.

GSK plc is reporting modest revenue growth of 1.5%. Earnings are also growing at 8.4%, indicating improving profitability.

GSK plc has a debt-to-equity ratio of 1.10×, reflecting a moderately high debt load — watch cash flow coverage. Its current ratio is 0.79×, suggesting it should be monitored for near-term liquidity.